Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes - Takeaways - MDSpire

Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes

  • By

  • Shuxia Zhang

  • Yi Chen

  • Haojie Qin

  • Jing Chen

  • Chunrong Chen

  • Xuemei Wu

  • Min Chen

  • Jiajun Lin

  • Fenge Yang

  • Meijuan Huang

  • July 14, 2026

Share

  • 1

    The study compared PK-guided and weight-guided coagulation factor replacement in hemophilia patients undergoing joint arthroplasty.

  • 2

    Thirty-three male patients with a median age of 39 years participated, with 75.8% having severe hemophilia.

  • 3

    The PK-guided group had significantly lower median hospitalization costs and coagulation factor consumption compared to the weight-guided group.

  • 4

    Median intraoperative blood loss and perioperative hemoglobin decrease were comparable between both replacement regimens.

  • 5

    The findings suggest that PK-guided therapy may offer clinical and economic advantages in managing hemophilia during arthroplasty.

Original Source(s)

Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes

  • by Shuxia Zhang, Yi Chen, Haojie Qin, Jing Chen, Chunrong Chen, Xuemei Wu, Min Chen, Jiajun Lin, Fenge Yang, Meijuan Huang

  • July 14, 2026

Related Content

Integrated multi-omics profiling of the early post-infarct heart reveals a hub gene network associated with myeloid-driven inflammation

From Peak Performance to Precision Healthcare

Travis Nemkov and Angelo D’Alessandro discuss how molecular profiling in elite athletes could inform personalized exercise, healthy aging, and cancer recovery

Case report: Diffuse large B-cell lymphoma associated with chronic inflammation presenting as a rapidly enlarging perigraft hematoma after TEVAR